In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status.
Where this comes from
- Record sourced from PubMed, PMID 38710083.
- Also identified by DOI 10.7326/J24-0025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. <b>Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial.</b> Circulation. 2024;149:204-216. 37952180.
Medical subject headings
- Glucagon-Like Peptides
- Heart Failure
- Obesity
- Quality of Life
- Weight Loss